ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstracts tagged "disease-modifying antirheumatic drugs and safety"

  • Abstract Number: 2403 • ACR/ARP Annual Meeting 2019

    Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings

    Tsutomu Takeuchi1, Yoshiya Tanaka 2, Mitsuhiro Rokuda 3, Hiroyuki Izutsu 3, Yuichiro Kaneko 3, Musashi Fukuda 3 and Daisuke Kato 3, 1Keio University School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Astellas Pharma, Inc., Tokyo, Japan

    Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in studies of Japanese, Korean and Taiwanese patients with RA. This analysis of…
Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology